EMA recommends restricting use of cancer medicine Rubraca

View source ↗

Summary

EMA recommends restricting the use of the cancer medicine Rubraca (rucaparib) to specific patient groups due to safety or effectiveness considerations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• RUBRACA (RUCAPARIB)